Zscaler Inc vs Zoetis Inc — how do they compare? Zscaler Inc trades at $148.75 (market cap $24.23B), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.78% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| ZS | ZTS | |
|---|---|---|
Market Cap | $24.23B | $31.95B |
Sector | Technology | Health |
52-Week High | $336.27 | $156.76 |
52-Week Low | $118.05 | $71.91 |
Enterprise Value | $22.55B | $39.24B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Zscaler trades at $148.72, down 0.78% on the day, with strong technical momentum showing bullish moving average signals and key support at $147. The company demonstrates robust revenue growth, increasing from $1.1B in 2022 to $2.67B in 2025, while narrowing net losses from -$390M to -$41M. Recent earnings beats and accelerating Zero Trust adoption position Zscaler for continued enterprise security market share gains amid growing cybersecurity spending trends.
Zscaler presents a compelling growth story with 79% analyst buy ratings and a $192.46 price target offering 29% upside potential. However, persistent profitability challenges, rising AI infrastructure costs, and ongoing class action investigations create near-term execution risks. The stock's premium valuation at 7.5x sales requires sustained revenue acceleration to justify current levels.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Trailing returns across standard periods
Latest headlines on both assets
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →